Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergan, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Allergan, Inc. - Product Pipeline Review - 2015', provides an overview of the Allergan, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Allergan, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Allergan, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Allergan, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Allergan, Inc.'s pipeline products Reasons To Buy - Evaluate Allergan, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Allergan, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Allergan, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Allergan, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Allergan, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Allergan, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Allergan, Inc. Snapshot 7 Allergan, Inc. Overview 7 Key Information 7 Key Facts 7 Allergan, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Allergan, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 Allergan, Inc. - Pipeline Products Glance 18 Allergan, Inc. - Late Stage Pipeline Products 18 Filing rejected/Withdrawn Products/Combination Treatment Modalities 18 Phase III Products/Combination Treatment Modalities 19 Allergan, Inc. - Clinical Stage Pipeline Products 20 Phase II Products/Combination Treatment Modalities 20 Phase I Products/Combination Treatment Modalities 21 Allergan, Inc. - Early Stage Pipeline Products 22 Preclinical Products/Combination Treatment Modalities 22 Discovery Products/Combination Treatment Modalities 23 Allergan, Inc. - Drug Profiles 24 dihydroergotamine mesylate 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Aczone X 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AGN-229666 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 bimatoprost 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 bimatoprost SR 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 cyclosporine 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 desmopressin acetate 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 onabotulinumtoxin A 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 oxymetazoline hydrochloride 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 (bimatoprost + brimonidine tartrate) 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 abicipar pegol 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AGN-195263 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 beclomethasone dipropionate 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 brimonidine tartrate implant 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 lidocaine 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 senrebotase 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 AGN-223575 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 AGN-151200 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Drug to Agonize D2/D3 Receptors for Parkinson's Disease 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Drug to Agonize GABA Receptor for Epilepsy 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Drug to Inhibit Tyrosine Kinase for AMD 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule for Glaucoma 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Neurotoxin Program 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Allergan, Inc. - Pipeline Analysis 52 Allergan, Inc. - Pipeline Products by Target 52 Allergan, Inc. - Pipeline Products by Route of Administration 54 Allergan, Inc. - Pipeline Products by Molecule Type 55 Allergan, Inc. - Pipeline Products by Mechanism of Action 56 Allergan, Inc. - Recent Pipeline Updates 57 Allergan, Inc. - Dormant Projects 70 Allergan, Inc. - Discontinued Pipeline Products 71 Discontinued Pipeline Product Profiles 71 budesonide 71 dexamethasone 71 memantine hydrochloride 71 onabotulinumtoxin A 71 Allergan, Inc. - Company Statement 73 Allergan, Inc. - Locations And Subsidiaries 77 Head Office 77 Other Locations & Subsidiaries 77 Allergan, Inc. - Key Manufacturing Facilities 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables Allergan, Inc., Key Information 7 Allergan, Inc., Key Facts 7 Allergan, Inc. - Pipeline by Indication, 2015 9 Allergan, Inc. - Pipeline by Stage of Development, 2015 11 Allergan, Inc. - Monotherapy Products in Pipeline, 2015 12 Allergan, Inc. - Combination Treatment Modalities in Pipeline, 2015 13 Allergan, Inc. - Partnered Products in Pipeline, 2015 14 Allergan, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 15 Allergan, Inc. - Out-Licensed Products in Pipeline, 2015 16 Allergan, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 17 Allergan, Inc. - Filing rejected/Withdrawn, 2015 18 Allergan, Inc. - Phase III, 2015 19 Allergan, Inc. - Phase II, 2015 20 Allergan, Inc. - Phase I, 2015 21 Allergan, Inc. - Preclinical, 2015 22 Allergan, Inc. - Discovery, 2015 23 Allergan, Inc. - Pipeline by Target, 2015 53 Allergan, Inc. - Pipeline by Route of Administration, 2015 54 Allergan, Inc. - Pipeline by Molecule Type, 2015 55 Allergan, Inc. - Pipeline Products by Mechanism of Action, 2015 56 Allergan, Inc. - Recent Pipeline Updates, 2015 57 Allergan, Inc. - Dormant Developmental Projects,2015 70 Allergan, Inc. - Discontinued Pipeline Products, 2015 71 Allergan, Inc., Subsidiaries 77 Allergan, Inc., Key Manufacturing Facilities 81
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.